Retinal Research Institute – Phoenix
Retinal Consultants of Arizona has a strong commitment to medical research and the advancement of treatments for retinal diseases. Unfortunately, there are many medical conditions that do not have a “cure.” Although we provide the latest technology available to treat retinal disorders, we are actively involved in multiple clinical research trials in hopes of expanding our treatment options for our patients. RCA physicians contribute to the advancement of new therapies by participating in clinical research studies.
We have been participating in clinical trials since 1998 and are proud that the Retinal Research Institute has become one of the nation’s largest retina & vitreous-specific research organizations. In many instances, RCA is the only retina group in Arizona to offer patient participation in multiple studies addressing multiple eye conditions
Mission / Purpose
Retinal Consultants of Arizona’s mission is to provide the most up to date and effective treatments for patients with retinal diseases.
News
Keep up with new research and findings from recent studies and trials.
Current Studies & Trials
Find out what current studies and trials we are enrolling for.
Interested in a Clinical Trial?
If you or someone you know is interested in more information about our clinical research trials, please contact us.
USC & RCA Create Collaboration
/ News /by retinalconsultantsUSC EYE INSTITUTE AND RETINAL CONSULTANTS OF ARIZONA UNITE TO ENRICH OPHTHALMIC SERVICES AFFILIATION CREATES JOINT INTERNATIONAL FELLOWSHIP AND INTEGRATED CLINICAL RESEARCH PROGRAMS The USC Eye Institute and Retinal Consultants of Arizona are proud to announce a new collaboration enhancing eye care with a specific focus on a joint educational and research programs. The USC-RCA […]
FDA Approves 1st Drug for Diabetic Retinopathy
/ Uncategorized /by retinalconsultantsFDA Approves 1st Drug for Diabetic Retinopathy To be used in those with diabetic macular edema, injections fight leading cause of blindness FDA Approves 1st Drug for Diabetic Retinopathy By Dennis Thompson HealthDay Reporter FRIDAY, Feb. 6, 2015 (HealthDay News) — The U.S. Food and Drug Administration on Friday approved the drug Lucentis (ranibizumab) to […]